BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

Core Insights - BridgeBio Pharma, Inc. is set to release topline results from the CALIBRATE Phase 3 trial for autosomal dominant hypocalcemia type 1 (ADH1) on October 28, 2025, before market opening [1] - A conference call will be held by management at 8:00 a.m. ET on the same day to discuss the trial data [1] Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - Founded in 2015, the company has a pipeline that includes programs from early science to advanced clinical trials [3] - The team consists of experienced professionals dedicated to applying advances in genetic medicine to benefit patients quickly [3]